other_material
confidence high
sentiment positive
materiality 0.85
Kymera reports positive Phase 1 data for oral STAT6 degrader KT-621; >90% STAT6 degradation at low doses
Kymera Therapeutics, Inc.
- SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.
- MAD: complete STAT6 degradation in blood and skin at doses ≥50 mg; safety undifferentiated from placebo with no SAEs.
- Th2 biomarkers: median TARC -37%, Eotaxin-3 -63% at Day 14, comparable or superior to dupilumab in healthy volunteers.
- KT-621 well-tolerated: no TRAEs in >1 subject, no severe AEs, no discontinuations, no clinically relevant lab/ECG changes.
- Next steps: Phase 1b AD data Q4 2025; Phase 2b AD start Q4 2025, asthma Q1 2026, enabling parallel Phase 3 readiness.
item 7.01item 8.01item 9.01